The Relationship Between Cancer and Functional and Structural Markers of Subclinical Atherosclerosis: A Systematic Review and Meta-Analysis

Yuhong Diao†, Zhixing Liu†, Li Chen*, Weiping Zhang and Dandan Sun*

Department of Ultrasound Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, China

Objectives: The relationship between cancer and subclinical atherosclerosis has always been the focus of people's attention. We conducted a systematic review and meta-analysis by evaluating the effects of cancer on functional and structural markers of subclinical atherosclerosis: intima-media thickness (IMT), pulse wave velocity (PWV), and flow-mediated vasodilation (FMD).

Methods: A comprehensive and systematic literature search was conducted on the internet. Sensitivity analysis, publication bias, standard mean difference (SMD), corresponding 95% confidence interval (95% CI), and subgroup analysis were performed for all relevant research indicators in the retrieved literature.

Results: Forty-six studies were included, including 3,729 cancer patients and 2,404 healthy controls. Cancer patients had significantly thicker IMT \[SMD (95\% CI) = 0.290 (0.069 to 0.511), P = 0.010\] and higher PWV \[SMD (95\% CI) = 0.392 (0.136 to 0.647), P = 0.003\] compared with healthy controls. There was no significant difference in FMD \[SMD (95\% CI) = −0.192 (−0.527 to 0.144), P > 0.05\]. After subgrouping by age, male proportion, and treatment, the analysis results of IMT ≥ 50 years old, PWV and FMD < 50 years old, male proportion ≥ 50%, chemotherapy group, IMT and PWV radiotherapy group, and PWV endocrine therapy group were statistically significant \(P < 0.05\). There were no significant differences in other subgroup analyses, overall sensitivity analysis, and publication bias \(P < 0.05\).

Conclusions: Cancer may promote subclinical atherosclerosis, and change the functional and structural markers of subclinical atherosclerosis such as IMT and PWV. Early intervention and prevention should be pursued.

Keywords: cancer, intima-media thickness, pulse wave velocity, flow-mediated vasodilation, systematic review and meta-analysis
INTRODUCTION

The latest global cancer burden data for 2020 released by the World Health Organization’s International Agency for Research on Cancer (IARC) shows that there were 19.29 million new cancer cases and 9.96 million cancer deaths worldwide in 2020. Cancer has become a common disease with high mortality and morbidity worldwide (1, 2), but with the progress of cancer treatment, the 5-year survival rate of cancer patients is getting higher and higher, and cancer has now become a chronic disease (2). At present, many studies show that cancer patients die from cardiovascular diseases in addition to cancer recurrence (3–6). The incidence of atherosclerosis in cancer patients is very high (4), which may be related to the systemic inflammatory response and impaired vascular endothelial function caused by the mechanism of cancer cell infection and corresponding chemoradiotherapy. Cancer patients all need to suffer from this change whether caused by simple cancer infection or its treatment. However, early detection and timely intervention can avoid the occurrence of atherosclerosis and even cardiovascular accidents.

Intima-media thickness (IMT), flow-mediated vasodilation (FMD), and pulse wave conduction velocity (PWV) are considered markers of atherosclerosis and provide important information about artery function and structure (7). These three markers have been widely used to evaluate subclinical atherosclerosis in order to improve prognosis and timely individualized treatment. Some studies have shown increased IMT, PWV, and reduced FMD in cancer patients compared to healthy controls (8–11). Conversely, some studies have produced inconsistent results (12–14). Currently, it is still controversial that cancer causes subclinical atherosclerosis and increased risk of cardiovascular disease, therefore we conducted this meta-analysis to further determine the relationship between cancer and subclinical atherosclerosis.

Since the available results are controversial, we conducted this meta-analysis to further evaluate differences in IMT, PWV, and FMD caused by cancer and to clarify the association between cancer and subclinical atherosclerosis.

ARTICLE TYPES

Systematic Review articles. Our systematic reviews conform to the reporting guideline PRISMA.

MANUSCRIPT FORMATTING

Materials and Methods

Publication Search

We searched the databases of PubMed, Web of Science, and Medline for articles concerning the relationship among the effects of cancer infection or related treatments on functional and structural markers of the vasculature (IMT, FMD, and PWV). The articles published between the earliest available dates to 5 August 2021 were applied. The key terms were as follows: “IMT” or “intima media thickness” and cancer or “flow-mediated dilatation” or “FMD” and cancer or “PWV” or “pulse wave velocity” and cancer.

Study Selection

Articles searched through the above retrieval methods were further screened using the following criteria. Figure 1 shows the filtering process of the studies.

Inclusion Criteria
1. The study should provide IMT, PWV, and/or FMD values.
2. The study should contain at least 2 independent groups or subgroups, 1 diagnosed with cancer and the other included healthy control subjects.

Exclusion Criteria
1. Find duplicate papers and keep one.
2. Take out reviews, case reports, letters, animal studies, and previous meta-analysis articles.
3. The study retrieved by abbreviations was not the markers of the vasculature.
4. No papers available in full.
5. The study was not published in English.

Data Extraction and Management

The data of the studies after the inclusion criteria and exclusion criteria were searched and extracted by two authors, describing the information to be collected is as follows: author, country, region, year, study design, site measured, sample size, mean age, the proportion of male, proportion of hypertension, proportion of smokers, proportion of patients with diabetes, the proportion of patients with hypertension, mean body mass index, mean systolic blood pressure, mean diastolic blood pressure, mean fasting blood glucose, mean total cholesterol, mean triglyceride, mean high-density lipoprotein, mean low-density lipoprotein, inflammatory markers, and the values of IMT, PWV, and FMD.

Data and Statistical Analysis

All of the study outcomes (values of IMT, PWV, and FMD) were transformed into mean and SD forms, which were performed using STATA 12.0 software (Stata Corp. College Station, TX, USA). Considering that the study values were measured on different sites, we calculated the standardized mean differences (SMDs) and 95% confidence intervals (95% CIs). Statistical heterogeneity between studies was assessed with the value of I². If I² was more than 50%, a fixed-effects model was considered (15). If I² was no more than 50%, a random-effects model was applied. In the meantime, the sub-group analysis was used for potential confounders (mean age and male percentage). And univariate meta-regression analysis for the covariates (sample size, age, sex, region, and site measured) was also conducted. In addition, the sensitivity analysis was performed by removing studies one by one to assess the impact of each study on the overall outcome (16). Using funnel plots, the Begg model and Egger test evaluated qualitatively publication bias.
RESULTS

Characteristics of Identified Studies

The search process is presented in the flow chart (Figure 1). In total, 3,961 articles were identified. According to the inclusion and exclusion criteria, 46 articles were finally applied in the meta-analysis, of which 25 could be used for IMT, 14 studies included PWV, and 18 studies reported FMD values (8–14, 17–55) (Supplementary Materials Supplementary Tables S1–3). The articles were selected from different regions. Nine of the articles are from Asia, 22 are from Europe, 12 are from North America and two are from South America. They were published from 1991 to 2021. Their average age ranged from 9.5 to 70.6, and the proportion of men ranged from 0 to 100 percent. Their treatment methods are complex and varied, including radiotherapy, chemotherapy, endocrine therapy, and mixed treatment or early untreated treatment. In addition, different articles measured IMT, PWV, and FMD at different anatomical sites. More clinical characteristics included in the study, such as smokers, BMI, blood pressure, fasting glucose, and lipid ratio, are shown in Supplementary Table S4 of the online Supplementary Materials table.

The Relationship of Cancer and IMT

After analyzing the 25 articles comprising 1,927 cancer patients and 1,077 healthy controls collected, we concluded that the IMT of patients with cancer was significantly increased than that of controls without cancer [SMD (95% CI) = 0.290 (0.069–0.511),
TABLE 1 | IMT, PWV, and FMD between patients with cancer and controls without cancer in overall and sub-group meta-analyses by age and female ratio.

| Variables | Group       | N   | SMD(95%CI)       | p    | I² (%) | P_{hetero} |
|-----------|-------------|-----|-----------------|------|--------|------------|
| IMT       | All         | 25  | 0.290 (0.069 to 0.511) | 0.010 | 85.9   | <0.001     |
| Age, years| <50         | 16  | 0.202 (−0.050 to 0.455) | 0.116 | 84.0   | <0.001     |
|           | ≥50         | 9   | 0.451 (0.020 to 0.883) | 0.040 | 87.5   | <0.001     |
| Male, %   | <50         | 13  | 0.171 (−0.156 to 0.497) | 0.306 | 85.1   | <0.001     |
|           | ≥50         | 12  | 0.417 (0.097 to 0.738) | 0.011 | 87.5   | <0.001     |
| Therapy   | Radiotherapy| 12  | 0.713 (0.418 to 1.008) | <0.001 | 76.6   | <0.001     |
|           | Chemotherapy| 6   | 0.795 (0.108 to 1.481) | 0.023 | 91.9   | <0.001     |
|           | Endocrine therapy | 3 | −0.350 (−0.742 to 0.043) | 0.081 | 47.6   | 0.149      |
|           | Other       | 4   | 0.018 (−0.112 to 0.148) | 0.786 | 0       | 0.628      |
| PWV       | All         | 14  | 0.392 (0.136 to 0.647) | 0.003 | 77.0   | <0.001     |
| Age, years| <50         | 5   | 0.448 (0.196 to 0.702) | 0.001 | 34.0   | 0.195      |
|           | ≥50         | 9   | 0.346 (−0.035 to 0.727) | 0.075 | 84.2   | <0.001     |
| Male, %   | <50         | 7   | 0.406 (−0.075 to 0.888) | 0.008 | 83.2   | <0.001     |
|           | ≥50         | 7   | 0.350 (0.088 to 0.612) | 0.009 | 63.9   | 0.011      |
| Therapy   | Radiotherapy| 3   | 0.704 (0.325 to 1.083) | <0.001 | 66.9   | 0.049      |
|           | Chemotherapy| 5   | 0.463 (0.020 to 0.905) | 0.040 | 73.0   | 0.005      |
|           | Endocrine therapy | 1 | 1.081 (0.220 to 1.943) | 0.014 | -      | -          |
|           | Other       | 5   | 0.068 (−0.287 to 0.423) | 0.706 | 64.8   | 0.023      |
| FMD       | All         | 18  | −0.192 (−0.527 to 0.144) | 0.263 | 88.2   | <0.001     |
| Age, years| <50         | 9   | −0.520 (−0.915 to −0.125) | 0.010 | 89.4   | <0.001     |
|           | ≥50         | 9   | 0.214 (−0.444 to 0.872) | 0.523 | 85.6   | <0.001     |
| Male, %   | <50         | 13  | 0.099 (−0.374 to 0.572) | 0.681 | 84.1   | <0.001     |
|           | ≥50         | 5   | −0.797 (−1.351 to −0.242) | 0.005 | 93.5   | <0.001     |
| Therapy   | Radiotherapy| 2   | 1.638 (−0.554 to 3.831) | 0.143 | 90.4   | 0.001      |
|           | Chemotherapy| 7   | −0.863 (−1.682 to −0.023) | 0.044 | 91.4   | <0.001     |
|           | Endocrine therapy | 3 | −0.028 (−0.658 to 0.601) | 0.930 | 67.3   | 0.047      |
|           | Other       | 6   | −0.085 (−0.209 to 0.038) | 0.176 | 0      | 0.997      |

The results are in bold if p < 0.05.
N, number; SMD, standard mean difference; CI, confidence interval; P_{hetero}, p value of heterogeneity; IMT, intima-media thickness; PWV, pulse wave velocity; FMD, flow-mediated vasodilation.

Because $I^2 = 85.9\%$ and $P < 0.001$, which represented significant heterogeneity, the random-effects model was conducted in the meta-analysis. In terms of sub-group analyses, there was a thicker IMT in the following subgroups: age $\geq 50$ years [SMD (95% CI = 0.451 (0.020, 0.883), $P = 0.040$), male ratio $\geq 50$% [SMD (95% CI = 0.451 (0.020, 0.883), $P = 0.011$], radiotherapy group [SMD (95% CI) = 0.713 (0.418, 1.008), $P < 0.001$], and chemotherapy group [SMD (95% CI) = 0.795(0.108, 1.481), $P = 0.023$] (Table 1). There was no significant change in the SMD (95%CI) by taking out studies one by one (Supplementary Materials Supplementary Table S5). Beyond that, the results of the Begg test ($P = 0.834$) and Egger test ($P = 0.566$) didn’t show significant publication bias (Table 2). Analysis of subgroup, analysis of sensitivity, and meta-regression (Supplementary Materials Supplementary Table S8) failed to explain the source of heterogeneity.

The Relationship of Cancer and PWV
The conclusion that PWV was visibly increased in patients with cancer was suggested by comparing the summarized data of patients with cancer and healthy controls, SMD of 0.392 (95% CI = 0.136–0.647, $P = 0.003$) (Table 1; Figure 2). There was significant heterogeneity, $I^2 = 77.0\%$. In terms of sub-group analyses, there was a higher PWV values in the following subgroups: age $< 50$ years [SMD (95% CI = 0.448 (0.195, 0.702), $P = 0.001$), male ratio $\geq 50$% [SMD (95% CI) = 0.350 (0.088, 0.612), $P = 0.009$], radiotherapy group [SMD (95% CI) = 0.704 (0.325, 1.083), $P < 0.001$], chemotherapy group [SMD (95% CI) = 0.463 (0.020, 0.905), $P = 0.040$], and endocrine therapy group [SMD (95% CI) = 1.081 (0.220, 1.943), $P = 0.014$] (Table 1). There was no obvious publication bias from the results of the Begg test ($P = 0.743$) and Egger test ($P = 0.501$) (Table 2). There was no significant change in the SMD (95%CI) by taking out studies one by one (Supplementary Materials Supplementary Table S6). Moreover, analysis of subgroup, analysis of sensitivity, and meta-regression (Supplementary Materials Supplementary Table S8) failed to explain the source of heterogeneity.
The Relationship of Cancer and FMD

Eighteen eligible studies were finally identified, involving 1,074 cancer patients and 672 healthy controls. The SMD of $-0.192$ (95% CI = $-0.527$ to $0.144$, $P = 0.263$) was no significance (Table 1; Figure 4). The $I^2$ statistic was 88.2%. In terms of sub-group analyses, there was a lower FMD in the following subgroups: age < 50 years [SMD (95% CI) = $-0.520$ ($-0.915$, $-0.125$), $P = 0.010$], male ratio $\geq$ 50% [SMD (95% CI) = $-0.797$ ($-1.351$, $-0.242$), $P = 0.005$], and chemotherapy group [SMD (95% CI) = $-0.853$ ($-1.682$, $-0.023$), $P = 0.044$] (Table 1). The Begg test ($P = 0.743$) and Egger test ($P = 0.501$) was no obvious publication bias (Table 2). There was no significant change in the SMD (95%CI) by taking out studies one by one (Supplementary Materials Supplementary Table S7). Analysis of subgroup, analysis of sensitivity, and meta-regression (Supplementary Materials Supplementary Table S8) failed to explain the cause of meaningless.

### TABLE 2 | Publication bias evaluated by Begg’s and Egger’s tests.

| Study ID | Begg Test | Egger Test | Egger Test |
|----------|-----------|------------|------------|
|           | Z Value   | P-Value    | t Value    | P-Value    |
| IMT       | 0.21      | 0.834      | 0.58       | 0.566      |
| PWV       | 0.33      | 0.743      | -0.69      | 0.501      |
| FMD       | 0.00      | 1.000      | -0.08      | 0.935      |

IMT, intima-media thickness; PWV, pulse wave velocity; FMD, flow-mediated vasodilation.

### FIGURE 2 | Forest plot of intima-media thickness in patients with cancer and controls without cancer. SMD, standard mean difference; CI, confidence interval.
DISCUSSION

To provide evidence for the impact of cancer on arterial structure and function (IMT, PWV, and FMD) in relation to subclinical atherosclerosis, we pooled data from 46 full-text articles and conducted a meta-analysis of available data from 3,729 cancer patients and 2,404 healthy controls. The results showed that cancer patients had more severe impairment of vascular structure and function, with thicker IMT and higher PWV than healthy subjects. The carotid artery is generally selected for IMT measurement, which can be obtained by ultrasound examination. The new ultrasound technology–ultrafast pulse wave velocity–can accurately and quickly obtain the carotid PWV. Subgroup analysis was performed to exclude the effects of age and sex on vascular structure and function. In addition, by analyzing and comparing different treatment methods in subgroups, it can be concluded that chemotherapy has a significant effect on functional and structural markers of subclinical atherosclerosis, such as IMT, PWV, and FMD, leading to show increased IMT, PWV, and reduced FMD. Radiotherapy also has a significant effect on IMT and PWV. Due to the relatively small sample size of the endocrine therapy group, its efficacy needs to be further determined. According to the results of the meta-analysis, cancer can promote the progression of atherosclerosis, damage vascular structure, and function, and increase the occurrence of cardiovascular risk. So, early detection and timely treatment can greatly improve the patients’ quality of life.

More cancer patients die from cardiovascular disease than from other causes (56). At present, subclinical atherosclerosis in tumor patients has always been the focus of attention, but the specific pathophysiological mechanism is still unclear. The progression of atherosclerosis is closely related to inflammatory response and immune dysregulation after cancer cell infection (57). Chronic persistent systemic inflammation can lead to loss of confluent luminal elastin layer and activation of glycoprotein in confluent lumen of the vascular wall, resulting in subcutaneous aggregation of low-density lipoprotein and increased circulating cholesterol in the body, thus triggering the expression of endothelial adhesion molecules and chemokine secretion, platelet-derived chemokine deposition and intimal immune cell infiltration (58–60). Besides, the multidirectional...
inflammatory factor MIF is closely related to LDL and can promote the occurrence and development of atherosclerosis. And many studies have confirmed the expression of MIF in various cancers (61–64).

Of course, antitumor drugs and chemoradiotherapy are also key causes of atherosclerosis. Radiotherapy is the key step leading to vascular injury. The vascular endothelium is sensitive to radiation, and its pathophysiological basis is direct damage to the vascular wall (65–68). Radiotherapy induces endothelial dysfunction, increases capillary permeability, activates inflammation, and leads to intimal hyperplasia, collagen formation and deposition, and fibrosis, which is conducive to the formation of atherosclerotic plaques (69). Testicular cancer patients who received chemotherapy were reported to have a 1.6 times higher risk of dying from cardiovascular disease 10 years after treatment than the general population (70). Cisplatin-based chemotherapy directly impairs vascular structure and function, increasing early cardiovascular events and vascular age at the time of treatment, but symptoms do not appear until many years have accumulated (71–74). Antimetabolites, antimicrobials, and tyrosine kinase inhibitors are chemotherapeutic agents with a high risk of atherosclerosis.

Cancer and atherosclerosis share common risk factors, such as age, smoking, a high-sugar, high-fat diet, and a sedentary lifestyle (75). Cancer patients often have metabolic abnormalities, especially glucose metabolism and lipoprotein abnormalities (76). The proliferation of cancer cells and the apoptosis of normal cells disrupt homeostasis. Dyshomeostasis leads to the development of atherosclerosis (77).

Men with cancer in our study were more likely to develop atherosclerosis than women. This may be related to higher levels of estrogen in women, which limits inflammation, increases nitric oxide production, and inhibits endothelial cell apoptosis (78). This finding is consistent with previous reports (79).

Our meta-analysis has several limitations. First, only English articles are selected for analysis. Secondly, the source of heterogeneity between studies has not been identified. Multivariate logistic regression on a larger sample is needed in

FIGURE 4 | Forest plot of flow-mediated vasodilation in patients with cancer and controls without cancer. SMD, standard mean difference; CI, confidence interval.
the future to find the source of heterogeneity. Thirdly, some included studies lacked basic information, failed to conduct covariate analysis and adjustment for cardiovascular risk factors such as hypertension, diabetes, hyperlipidemia and smoking, failed to analyze the relationship between IMT, PWV, FMD and cholesterol level, failed to analyze inflammatory markers and other risk factors in cancer and health control databases, failed to show the association of the time point of the data was collected upon cancer diagnosis and treatment, and failed to judge whether the changes in IMT, PWV and FMD are cumulative responses over a long period of time after cancer treatment or short-term acute responses. Fourthly, the inclusion study excluded people who had already experienced a cardiovascular accident, and the cancer population in the study had a shorter follow-up period, so no association could be drawn between IMT, PWV, FMD and actual CAD event complications. Finally, the number of studies was insufficient and the sample size was small, leading to the failure to distinguish different types of cancer and to conduct subgroup analysis before and after treatment.

In conclusion, cancer promotes subclinical atherosclerosis, destroys functional and structural markers of blood vessels, and leads to higher IMT and PWV. The measurement of PWV and IMT values can be easily and quickly obtained by ultrasonic technology. Increased attention, early assessment, and timely prevention of atherosclerosis progression can reduce the incidence of cardiovascular accidents in cancer survivors.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

AUTHOR CONTRIBUTIONS

YD and DS contributed to the conception or design of the work. WZ, YD, and ZL contributed to the acquisition, analysis, or interpretation of data for the work. YD drafted the manuscript. DS, LC, and ZL critically reviewed the manuscript. All authors gave final approval and agree to be accountable for all aspects of work ensuring integrity and accuracy.

FUNDING

This article was funded by the Jiangxi Provincial Department of Science and Technology key research and development program general project (20203BBGL73196) and the Natural Science Foundation of Jiangxi Province (20212BAB206040).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2022.849538/full#supplementary-material

REFERENCES

1. Farzin L, Shamsipur M. Recent advances in deoxychemical affinity biosensors for low level detection of cancer protein biomarkers using nanomaterial- assisted signal enhancement strategies. J Pharm Biomed Anal. (2018) 147:185–210. doi: 10.1016/j.jpba.2017.07.042
2. Fiorica F, Stefanelli A, Pascale G, Fischella R. Elderly gastrointestinal cancer patients and radiochemotherapy: a review. Clin Ter. (2014) 165:57–61. doi: 10.7471/CT.2014.1662
3. Afifi AM, Saad AM, Al-Husseini MJ, Elmehrath AO, Northfelt DW, Sonbol MB. Causes of death after breast cancer diagnosis: A US population-based analysis. Cancer Apr 1, (2020) 126:1559–67. doi: 10.1002/cncr.32648
4. Oh C-M, Lee D, Kong H-J, Lee S, Won Y-J, Jung K-W, et al. Causes of death among cancer patients in the era of cancer survivorship in Korea: attention to the suicide and cardiovascular mortality. Cancer Med. (2020) 9:1741–52. doi: 10.1002/cam4.2813
5. Nguyen-Nielsen M, Møller H, Tjønneland A, Borre M. Causes of death in men with prostate cancer: results from the Danish prostate cancer registry (DAPROCdata). Cancer Epidemiol. (2019) 59:249–57. doi: 10.1016/j.canep.2019.02.017
6. Xie S-H, Chen H, Lagergren J. Causes of death in patients diagnosed with gastric adenocarcinoma in Sweden, 1970-2014: a population-based study. Cancer Sci. (2020) 111:2451–9. doi: 10.1111/cas.14441
7. Stein JH, Korcmarz CE, Hurst RT, Lonn E, Kendall CB, Möhler ER, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr. (2008) 21:93–111. doi: 10.1016/j.echo.2007.11.011
8. Shariat M, Alias NAA, Biswal BM. Radiation effects on the intima-media thickness of the common carotid artery in post-radiotherapy patients with head and neck malignancy. Postgrad Med J. (2008) 84:609–12. doi: 10.1136/pgmj.2008.068569
9. Yuan C, Wu VW, Yip SP, Kwong DL, Ying M. Ultrasound evaluation of carotid atherosclerosis in post-radiotherapy nasopharyngeal carcinoma patients, type 2 diabetics, and healthy controls. Ultraschall in der Medizin. (2017) 38:190–7. doi: 10.1055/s-0034-1399293
10. Dockery F, Rajkumar C, Agarwal S, Waxman J, Bulpitt CJ. Androgen deprivation in males is associated with decreased central arterial compliance and reduced central systolic blood pressure. J Hum Hypertens. (2000) 14:395–7. doi: 10.1038/sj.jhh.1001028
11. Giordano P, Muggeo P, Delvecchio M, Carbonara S, Romano A, Altomare M, et al. Endothelial dysfunction and cardiovascular risk factors in childhood acute lymphoblastic leukemia survivors. Int J Cardiol. (2017) 228:621–7. doi: 10.1016/j.ijcard.2016.11.025
12. Chrisoulidou A, Paziou-Panayiotou K, Georgiou E, Boudina M, Lytras K, Iakovou I, et al. The hypothalamic-pituitary-adrenal axis in women with differentiated thyroid cancer. Endocr Res. (2010) 35:137–43. doi: 10.3109/07435580.2010.496760
13. Sekijima T, Tanabe A, Maruoka R, Fujishiro N, Yu S, Fujisawa S, et al. Impact of platinum-based chemotherapy on the progression of atherosclerosis. Clinicaeretic. (2011) 14:31–40. doi: 10.3109/13697137.2010.522278
14. Vatanan A, Sarkola T, Ojala TH, Turaanlahi M, Jahunkainen T, Saarinen-Pihkala UM, et al. Radiotherapy-related arterial intima thickening and plaque formation in childhood cancer survivors detected with very-high resolution ultrasound during young adulthood. Pediatr Blood Cancer. (2015) 62:2000–6. doi: 10.1002/pbc.25616
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. (1986) 7:177–88. doi: 10.1016/0197-2456(86)90046-2
16. Bai R, Zhang Y, Liu W, Ma C, Chen X, Yang J, et al. The relationship of ankylosing spondylitis and subclinical atherosclerosis: a systemic review and meta-analysis. Angiology. (2019) 70:492–500. doi: 10.1177/0003319718814309
17. Beckman JA, Thakore A, Kalinowski BH, Harris JR, Creager MA. Radiation therapy impairs endothelium-dependent vasodilation in humans. *J Am Coll Cardiol.* (2001) 37:576–5. doi: 10.1016/S0735-1097(00)01190-6
18. Brouwer CAJ, Postma A, Hoeve Meijer HLH, Smit AJ, Vonk JM, Van Roon AM, et al. Endothelial damage in long-term survivors of childhood cancer. *J Clin Oncol.* (2013) 31:3906–13. doi: 10.1200/JCO.2012.46.6086
19. Chaouwannakit N, D’Agostino R, Hamilton CA, Lane KS, Ntim WO, Lawrence J, et al. Aortic stiffness increases upon receipt of anthracycline chemotherapy. *J Clin Oncol.* (2010) 28:166–72. doi: 10.1200/JCO.2009.23.8527
20. Dardano A, Ghiadoni L, Plantinga Y, Caraccio N, Bemi A, Duranti E, et al. Recombinant human thymropin reduces endothelium-dependent vasodilation in patients monitored for differentiated thyroid carcinoma. *J Clin Endocrinol Metab.* (2006) 91:4175–8. doi: 10.1210/jc.2006-0440
21. Dengel DR, Kelly AS, Zhang L, Hodges JS, Baker KS, Steinberger J. Signs of early sub-clinical atherosclerosis in childhood cancer survivors. *Pediatr Blood Cancer.* (2014) 61:532–7. doi: 10.1002/pbc.24829
22. Dengel DR, Kelly AS, Zhang L, Wang Q, Hodges JS, Steinberger J, et al. Vascular Structure and Function in Cancer Survivors after Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant.* (2019) 25:151–6. doi: 10.1016/j.bbmt.2018.08.005
23. Ederer AK, Didier KD, Reiter LK, Brown M, Hardy R, Caldwell J, et al. Influence of Adjuvant Therapy in Cancer Survivors on Endothelial Function and Skeletal Muscle Deoxygenation. *PLoS ONE.* (2016) 11:e0147691. doi: 10.1371/journal.pone.0147691
24. Feely RS, McGuirt WF, Bond MG, Strickland HL, Craven TE, Hilbrand JB. Irradiation. A significant risk factor for carotid atherosclerosis. *Arch Otolaryngol Head Neck Surg.* (1991) 117:1135–7. doi: 10.1001/archotol.1991.01870220083014
25. Gianicolo ME, Gianicolo EAL, Tramacere F, Andreassi MG, Portaluri A, et al. Assessment of increased risk for cardiovascular disease. *J Clin Biochem Nutr.* (2010) 47:36–10. doi: 10.3164/jcbn.2010-70
26. Gilbert SE, Tew GA, Bourke L, Winter EM, Rosario DJ. *Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol.* (2010) 28:166–72. doi: 10.1200/JCO.2009.23.8527
27. Huang T-L, Hsu H-C, Chen H-C, Lin H-C, Chien C-Y, Fang F-M, et al. Endothelial damage in long-term survivors of childhood cancer. *J Adolesc Young Adult Oncol.* (2015) 4:844–50. doi: 10.1098/jayao.2017.0075
28. Jones LW, Fels DR, West M, Allen JD, Broadwater G, Barry WT, et al. Anthra cycline-containing adjuvant chemotherapy. *J Appl Physiol.* (2009) 107:2122:aid-japn-19.3.002-1
29. Kinugawa Y, Hara T, Kimura M, Takahashi M, Okano M, et al. Evaluation of endothelial function and flow-mediated vasodilation in young survivors of childhood cancer. *Pediatr Blood Cancer.* (2016) 63:349–54. doi: 10.1002/pbc.25547
30. Krystal JI, Reppucci M, Mayr T, Fish JD, Sethna C. Arterial stiffness in childhood cancer survivors. *Pediatr Blood Cancer.* (2015) 62:1832–7. doi: 10.1002/pbc.25547
31. Liang K, Kwack WG, Lee YS, Hahn KB, Kim YK. Increased pulse wave velocity reflecting arterial stiffness in patients with colorectal adenomas. *J Clin Biochem Nutr.* (2012) 51:10–7. doi: 10.3164/jcbn.2012-10
32. Marlett KL, Steinberger J, Rudser KD, Dengel DR, Sadak KT, Lee JL, et al. The effect of atorvastatin on vascular function and structure in young adult survivors of childhood cancer: a randomized, placebo-controlled pilot clinical trial. *J Adolesc Young Adult Oncol.* (2019) 8:442–50. doi: 10.1098/jayao.2017.0075
33. Meerse KA, Siegel SE, Gilsanz V, Bernstein L, Nelson MB, Sposto R, et al. Premature carotid artery disease in pediatric cancer survivors treated with neck irradiation. *Pediatr Blood Cancer.* (2009) 55:615–21. doi: 10.1002/pbc.22111
34. Natri CI, Martins WP, Ferriani RA, Filho FM, Dos Reis FJC. Sonographic evaluation of endothelial function in letrozole and tamoxifen users. *Maturitas.* (2008) 61:340–4. doi: 10.1016/j.maturitas.2008.09.019
35. Okur A, Karadenziz C, Özhan Oktar S, Pinarli FG, Aral A, Ozguz A. Assessment of brachial artery reactivity, carotid intima-media thickness, and adhesion molecules in pediatric solid tumor patients treated with anthracyclines. *Pediatr Hematol Oncol.* (2016) 33:178–85. doi: 10.3109/088808018.2016.1146575
36. Sadurska E, Brodzisz A, Zaucha-Prazmo A, Kowalczyk J. The estimation of intima-media thickness and cardiovascular risk factors in young survivors of childhood cancer. *J Pediatr Hematol Oncol.* (2016) 38:549–54. doi: 10.1097/MPH.0000000000001513
37. Simon T, Boutousiey P, Simon JM, Laloux B, Tournigand C, Tropeano AI, et al. Influence of tamoxifen on carotid intima-media thickness in postmenopausal women. *Circulation.* (2002) 106:2925–9. doi: 10.1161/01.CIR.106.12.2925
38. Siviero-Miachon AA, Spinola-Castro AM, de Martino LE, de Castro Monteiro CM, de Camargo Carvalho AC, Calixto AR, et al. Subcutaneous adipose tissue plays a beneficial effect on subclinical atherosclerosis in young survivors of acute lymphocytic leukemia. *Vasc Health Risk Manag.* (2015) 11:479–88. doi: 10.1177/1551243314567883
39. Stamatelopoulos KS, Lekakis JP, Poulakaki NA, Papamichael CM, Venetasou K, Aznauirdis K, et al. Tamoxifen improves endothelial function and reduces carotid intima-media thickness in postmenopausal women. *Am Heart J.* (2004) 147:1093–9. doi: 10.1016/j.ahj.2003.12.029
40. Stellwagen J, Lubberts S, Stegink LC, Steursma G, Kruit LM, Donkerbroek JW, et al. Vascular aging in long-term survivors of testicular cancer more than 20 years after treatment with cisplatin-based chemotherapy. *Br J Cancer.* (2020) 123:1599–607. doi: 10.1038/s41416-020-01049-3
41. Stridheder K, Hellwig S, Renauw H, Van Bonn S, Schraven SP, Mlynisky R, et al. Screening for irradiation vasculopathy by intima-media thickness sonography in head and neck cancer patients. *Eur Arch Otorhinolaryngol.* (2021) 278:2021–26. doi: 10.1007/s00461-020-06501-3
42. Sutterfield SL, Caldwell JT, Post HK, Lovoy GM, Mohler ER, Ade CJ. Lower cutaneous microvascular reactivity in adult cancer patients receiving chemotherapy. *J Appl Physiol.* (2018) 125:1141–9. doi: 10.1152/japplphysiol.00394.2018
43. Tesarova P, Kalousova M, Zima T, Suchanek M, Malivka I, Kvasnicka J, et al. Endothelial activation and flow-mediated vasodilation in young patients with breast cancer. *Neoplasma.* (2013) 60:690–7. doi: 10.4149/neop_2013_088
44. Vassilakopoulou M, Mountziros G, Mamopoulos C, Protogerou A, Aznauirdis K, Katsichi P, et al. Paclitaxel chemotherapy and vascular toxicity as assessed by flow-mediated and nitrate-mediated vasodilation. *Vasc Pharmacol.* (2010) 53:115–21. doi: 10.1016/j.vph.2010.05.002
45. Vaughn DJ, Palmer SC, Carver JR, Jacobs LA, Mohler ER. Cardiovascular risk in long-term survivors of testicular cancer. *Circulation.* (2008) 112:1949–53. doi: 10.1161/jaha.110.000248
46. Ye J, Rong X, Xiang Y, Xing Y, Tang Y, A study of radiation-induced cerebral vascular injury in nasopharyngeal carcinoma patients
with radiation-induced temporal lobe necrosis. PLoS ONE. (2012) 7:e42890. doi: 10.1371/journal.pone.0042890

53. Yersal Ö, Eryilmaz U, Aksam H, Meydan N, Barutca S. Arterial stiffness in breast cancer patients treated with anthracycline and trastuzumab-based regimens. Cardiol Res Pract. (2018) 2018:5352914. doi: 10.1155/2018/5352914

54. Zaletel LZ, Poppit M, Zaletel M. Is Carotid stiffness a possible surrogate for stroke in long-term survivors of childhood cancer after neck radiotherapy? Radiol Oncol. (2018) 52:136–42. doi: 10.2478/raon-2018-0006

55. Zhang Z, Luo R, Tan B, Qian J, Duan Y, Wang N, et al. Carotid artery stiffness evaluated early by wave intensity in normal left ventricular function in post-radiotherapy patients with nasopharyngeal carcinoma. J Med Ultrason. (2001) 45:301–6. doi: 10.1007/s10396-017-0817-2

56. Henson KE, Reulen RC, Winter DL, Bright CJ, Filidier MM, Frobisher C, et al. Cardiac mortality among 200,000 five-year survivors of cancer diagnosed at 15 to 39 years of age: the teenage and young adult cancer survivor study. Circulation. (2016) 134:1519–31. doi: 10.1161/CIRCULATIONAHA.116.022514

57. Puri R, Nissen SE, Libby P, Shao M, Ballantyne CM, Barter P, et al. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy. Circulation. (2013) 128:2395–403. doi: 10.1161/CIRCULATIONAHA.113.04243

58. Kwon GP, Schroeder JL, Amar MJ, Remaley AT, Balaban RS. Contribution of macromolecular structure to the retention of low-density lipoprotein at arterial branch points. Circulation. (2008) 117:2919–27. doi: 10.1161/CIRCULATIONAHA.107.754614

59. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. (2011) 12:204–12. doi: 10.1038/ni.2001

60. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. (2011) 17:1410–22. doi: 10.1038/nm.2538

61. Hauser S, Kaminski A, Syring I, Holderenried S, Diekmann K-P, Muller SC, et al. Evaluation of serum biomarkers (FGF-2, HGF, MIF and PTN) in patients with testicular germ cell cancer. In vivo. (2019) 33:1935–40. doi: 10.21873/in vivo.11688

62. Avalos-Narváez G, Muñoz-Valle JE, Daneri-Narváez A, Quintero-Ramos A, Franco-Topté R, Morán-Mendoza Adj, et al. Circulating soluble levels of MIF in women with breast cancer in the molecular subtypes: relationship with Th17 cytokine profile. Clin Exp Med. (2019) 19:385–91. doi: 10.1007/s10238-019-00559-6

63. Klemke L, de Oliveira T, Witt D, Winiker N, Bohnenberger H, Buca R, et al. Hsp90-stabilized MIF supports tumor progression via macrophage recruitment and angiogenesis in colorectal cancer. Cell Death Dis. (2021) 12:155. doi: 10.1038/s41419-021-03426-2

64. Jäger B, Klatt D, Flappend L, Golpion H, Lienenklaus S, Barbosa PD, et al. CXCR4/MIF axis amplifies tumor growth and epithelial-mesenchymal interaction in non-small cell lung cancer. Cell Signal. (2020) 73:109672. doi: 10.1016/j.cellsig.2020.109672

65. Milliat F, François A, Tamarat R, Benderitter M. Role of endothelial cell apoptosis. Annales de cardiologie et d'anesthésie. (2008) 57:139–48. doi: 10.1016/j.an card.2008.02.015

66. Gaugler MH, Squiban C, Mouton MA, Gourmelon P, van der Meeren A. Irradiation enhances the support of haemopoietic cell transmigration, proliferation and differentiation by endothelial cells. Br J Haematol. (2001) 113:940–50. doi: 10.1046/j.1365-2141.2001.02852.x

67. van Kleef E, Verheij M, Ossoren Y, Dewit L, Stewart F. In vitro and in vivo expression of endothelial von Willebrand factor and leukocyte accumulation after fractionated irradiation. Radiat Res. (2000) 154:375–81. doi: 10.1667/0033-7587(2000)154[0375:ivawe]2.0.co;2

68. Soucy KG, Lim HK, Benjo A, Santhanam L, Ryoo S, Shoukas AA, et al. Single exposure gamma-irradiation amplifies xanthine oxidase activity and induces endothelial dysfunction in rat aorta. Radiat Environ Biophys. (2007) 46:179–86. doi: 10.1007/s00411-006-0090-z

69. Raposeiras Roubin S, Cordero A. The Two-way Relationship Between Cancer and Atherosclerosis. Revista espanola de cardiología. (2019) 72:487–94. doi: 10.1016/j.rec.2018.12.010

70. Lauritsen J, Hansen MK, Bandak M, Kreibberg MB, Skott JW, Wagner T, et al. Cardiovascular risk factors and disease after male germ cell cancer. J Clin Oncol. (2020) 38:584–92. doi: 10.1200/JCO.19.01180

71. Feldman DR, Schaffer WL, Steinagtt RM. Late cardiovascular toxicity following chemotherapy for germ cell tumors. J Natl Compr Canc Netw. (2012) 10:537–44. doi: 10.6004/jnccn.2012.0051

72. Lubberts S, Meijer C, Demaria M, Gietema JA. Early ageing after cytotoxic treatment for testicular cancer and cellular senescence: time to act. Crit Rev Oncol Hematol. (2020) 151:102963. doi: 10.1016/j.critrevonc.2020.102963

73. Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. (2009) 53:2231–47. doi: 10.1016/j.jacc.2009.02.050

74. Aichberger KJ, Herndholzer S, Schrenthaner G-H, Schillinger M, Mitterbauer-Hohendanner G, Sillaber C, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. (2011) 86:533–9. doi: 10.1002/ajh.22037

75. Cordero A, Falciai L, Garcia-Carrilero M, Gunturiz C, Montagud V, Núñez J. Breakfast habits in patients hospitalized for acute coronary syndrome. Revista espanola de cardiología. (2015) 68:814–5. doi: 10.1016/j.rec.2015.05.007

76. de Haas EC, Oosting SE, Lefrandt JD, Wolfenbuttel BH, Sleijfer DT, Gietema JA. The metabolic syndrome in cancer survivors. Lancet Oncol. (2010) 11:193–203. doi: 10.1016/S1470-2045(09)70287-6

77. Narula J, Nakano M, Virmani R, Kologidje FD, Petersen R, Newcomb R, et al. Histopathological characteristics of atherosclerotic coronary disease and implications of the findings for the invasive and noninvasive detection of vulnerable plaques. J Am Coll Cardiol. (2013) 61:1041–51. doi: 10.1016/j.jacc.2012.10.054

78. Spyridopoulos I, Sullivan AR, Kearney M, Isner JM, Losordo DW. Estrogen-receptor-mediated inhibition of human endothelial cell apoptosis. Estradiol as a survival factor Circulation. (1997) 95:1505–14. doi: 10.1161/01.CIR.95.6.1505

79. Sun D, Wu Y, Yuan Y, Wang Y, Liu W, Yang J. Is the atherosclerotic process accentuated under conditions of HIV infection, antiretroviral therapy, and protease inhibitor exposure? Meta-analysis of the markers of arterial structure and function. Atherosclerosis. (2015) 242:109–16. doi: 10.1016/j.atherosclerosis.2015.06.059

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.